Neurobehavioral disturbances constitute an important
|
|
- Eric Lloyd
- 6 years ago
- Views:
Transcription
1 Differential Effects of L-Dopa and Subthalamic Stimulation on Depressive Symptoms and Hedonic Tone in Parkinson s Disease Karsten Witt, M.D. Christine Daniels, M.D. Jan Herzog, M.D. Delia Lorenz, M.D. Jens Volkmann, M.D. Julia Reiff, M.D. Maximilian Mehdorn, M.D. Günther Deuschl, M.D. Paul Krack, M.D. Patients with Parkinson s disease frequently have mild to moderate depression and exhibit low hedonic tone. The authors investigate the impact of a single L-dopa challenge and the acute effects of electric stimulation of the subthalamic nucleus (STN) on symptoms of depression and hedonic tone. Depressive symptoms improved with L-dopa and STN stimulation to the same extent. However, hedonic tone improved only with L-dopa. Most of the emotional changes did not correlate with changes in motor performance, indicating they were not just reactive but specific to the treatment. These results demonstrate a single dissociation of depressive symptoms and anhedonia in response to an acute L-dopa and STN-stimulation challenge. (The Journal of Neuropsychiatry and Clinical Neurosciences 26; 18:397 1) Neurobehavioral disturbances constitute an important aspect in the spectrum of clinical manifestations of Parkinson s disease. 1,2 Thirty-eight percent of Parkinson s disease patients develop depression according to DSM-IV criteria. 3 Anhedonia, the inability to experience pleasure, is a typical feature of major depression, but it is also frequently associated with Parkinson s disease. The prevalence of anhedonia in Parkinson s disease patients is 7% to %, but low hedonic tone is not always related to depressive mood in Parkinson s disease.,5 Deep brain stimulation (DBS) of the subthalamic nucleus (STN) improves off-period motor functions in Parkinson s disease. 6 Several reports have described behavioral abnormalities in Parkinson s disease patients after DBS. 6 1 The interpretation of these longitudinal studies that examined patients before and after implantation of STN electrodes for DBS is complex. Behavioral problems might be the consequence of a post-operative decrease in dopaminergic medication and, therefore, might reflect the loss of psychotropic effects of the medication. Or, the reported changes in mood might be the result of specific effects of the STN stimulation itself. The goal of the present study was to investigate the effects of acute changes in STN stimulation and L-dopa on signs and symptoms of depression and on hedonic tone. METHOD We examined 15 Parkinson s disease patients (three women, 12 men, mean age of 57 years) before and 3 months after bilateral electrode implantation in the subthamamic nucleus for deep brain stimulation. All patients suffered from advanced Parkinson s disease (mean disease duration of 15 years [SD.8 years]). Their Hoehn and Yahr ratings raged from 2.5 to (mean 2.97 [SD.35]). None of them exhibited dementia (Mattis Dementia Rating Scale score 13). 11 The patients had quadripolar stimulating electrodes chronically implanted, as previously described. 12 Dopaminergic drugs were compared for dopa-equivalent dosages. 6 Patients received an average L-dopa equivalent Received June 3, 25; revised October 11, 25; accepted December 26, 25. Drs. Witt, Daniels, Herzog, Lorenz, Volkmann, and Deuschl are affiliated with the Department of Neurology, University Schleswig- Holstein, Campus Kiel, Germany. Dr. Reiff is affiliated with the Department of Psychiatry, Zentrum für Integrative Psychiatrie, Kiel, Germany. Dr. Mehdorn is affiliated with the Department of Neurosurgery, University Schleswig-Holstein, Campus Kiel, Germany. Dr. Krack is affiliated with the Department of Clinical and Biological Neurosciences, Service de Neurologie, Centre Hospitalier Universitaire de Grenoble, Grenoble, France. Address correspondence to Dr. Witt, Christian-Albrechts-Universität Kiel, Department of Neurology, Schittenhelmstrasse 1, D-215 Kiel, Germany; k.witt@neurologie.unikiel.de ( ). Copyright 26 American Psychiatric Publishing, Inc. J Neuropsychiatry Clin Neurosci 18:3, Summer
2 daily dosage of 915 mg before surgery and 9 mg 3 months after surgery. At the time of testing, the stimulation characteristics were as follows: monopolar stimulation, mean pulse width 6 lsec, average frequency 11 Hz, and mean stimulation voltage 3.2 V. The protocol was approved by the local ethical committee at Kiel University, and all patients gave informed consent. Pre-operatively, a Unified Parkinson Disease Rating Scale (UPDRS III) motor score was accorded in a medication-off condition following a 12-hour overnight withdrawal of dopaminergic medication, and in a medicationon condition after the intake of an L-dopa dose. We chose the L-dopa dose according to the individual amount necessary to induce an optimal motor response during preoperative clinical testing. Three months after electrode implantation, the L-dopa challenge was repeated in four combinations, always in the same chronological order: 1) medication off/stimulation off after a drug-free interval of 12 hours overnight; 2) medication off/stimulation on; 3) medication on/stimulation off using the same dose of L-dopa as pre-operatively; and ) medication on/stimulation on. The neurological examination (UPDRS III) and the psychiatric rating began 3 minutes after changing the drug to achieve a stable clinical status. We employed the Beck Depression Inventory (BDI) 13 to rate symptoms of depression. The items were divided into 12 cognitive-affective (psychological) and nine somatic (physiological) symptoms, according to a model by Endler et al. 1 To assess hedonic tone, we administered the German version of the Snaith-Hamilton Pleasure Scale (SHAPS), 15,16 a 1-item self-rating scale that covers four domains of hedonic experience: interest/pastimes, social interaction, sensory experience, and food/drink. Statistical Analysis We analyzed the UPDRS III data of the pre-operatively performed L-dopa testing by using a Wilcoxon test because the data showed no normal distribution. We analyzed the post-operative results of the UPDRS III and the self-rating scales using separate Wilcoxon tests because the data either showed no normal distribution (UPDRS III) or came from ordinal-scaled self-rating tests (e.g., BDI, SHAPS). To assess the effect of stimulation and medication, respectively, the comparison of the values UPDRS III, BDI cognitive-affective items, BDI somatic items and SHAPS were analyzed separately in the conditions stimulation off/medication off versus stimulation on/medication off, and stimulation off/medication off versus stimulation off/medication on. We analyzed the additive effect of stimulation and medication by testing the conditions stimulation off/medication on versus stimulation on/medication on (additive effect of stimulation), and the conditions stimulation on/medication off versus stimulation on/ medication on (additive effect of medication). Furthermore, we calculated correlations between cognitive/affective and somatic items of the BDI and SHAPS and between psychiatric and motor changes (UPDRS III) (Spearman correlation analysis, 2-tailed). The level of significance was set at.5. RESULTS UPDRS Motor Score A comparison of the preoperative motor changes with L-dopa showed a significant decrease of the UPDRS III after the single L-dopa challenge (Z 3.1, p.1). Post-operatively, the Wilcoxon test demonstrated a significant effect of medication (Z 3., p.1) and stimulation (Z 3., p.1) and a significant additive effect of medication (Z 3., p.1) and of stimulation (Z 2., p.) (Figure 1). Total Score of the BDI There was a significant effect of medication (Z 2.8, p.5) and stimulation (Z 3.2, p.1). Furthermore, the Wilcoxon test showed a significant additive effect of medication (Z 2.1, p.3) and a significant additive effect of stimulation (Z 2., p.). Cognitive Affective Items of the BDI There was a significant effect of medication (Z 2.7, p.6) and stimulation (Z 3.1, p.2). Moreover, there was a significant additive effect of medication (Z 2., p.) and a significant additive effect of stimulation (Z 2., p.) (Figure 1). Somatic Items of the BDI Statistical tests showed no significant effect of Mmdication (p.53) and stimulation (p.2) and no additive effect of medication (p.13) and stimulation (p.28) (Figure 1). SHAPS-D There was a significant effect of medication (Z 2.3, p.2) on the score of SHAPS, but no significant effect for stimulation (p.26) and a significant additive effect of medication (Z 2.3, p.2), but no significant additive effect of stimulation (p.7) (Figure 1) J Neuropsychiatry Clin Neurosci 18:3, Summer 26
3 WITT et al. Correlation Analysis Between Motor and Mood Changes Spearman s rho revealed a significant correlation between motor changes due to medication and stimulation (q.69, p.5). Furthermore, there was a single significant correlation between motor changes related to the medication and changes in the global BDI score caused by medication (q.57, p.28). All other correlations between motor and neuropsychiatric scores were insignificant. to imagine how their present mood state could affect the somatic items sleep or appetite, for example. On the other hand, acute significant changes were detected in the cognitive-affective items of the BDI and the SHAPS. This shows that these self-ratings are sensitive to rapid mood changes. This observation weakens the claim that the BDI scale is inflexible and not able to detect acute changes in the emotional state. Previous studies used other self-rating scales on the basis of visual analogue scales. 18,19 To avoid multiple DISCUSSION Whereas both L-dopa and STN stimulation had significant effects on motor signs and on depressive symptoms as measured by the BDI, only L-dopa significantly improved the hedonic tone measured by the SHAPS. These positive effects on mood in our study are in line with previous studies, demonstrating psychotropic effects of both L-dopa and STN stimulation. 17 STN stimulation, although improving motor symptoms to the same extent as L-dopa, showed no effect on the hedonic tone. The correlation analysis of motor and neuropsychiatric data showed only a positive correlation between the change in motor score change and the change of the BDI global score. The lack of any further correlation, especially the change in the cognitive affective items and the motor score due to stimulation and due to medication, argues against relevant interdependence of emotional and motor domains in this patient group. Both medication and stimulation led to comparable improvements in motor function. If a simple improvement of motor functions induced a reactive improvement in depressive symptoms, then one would expect correlations between motor and neuropsychiatric data after STN stimulation as well. There are some limitations to our study: the BDI assesses past depressive symptoms, usually over the past 7 days, and might be inadequate for detecting rapid changes in mood. Although our study indicates that BDI is indeed sensitive to acute changes in mood, this finding will need to be replicated in an independent sample. As the BDI contains somatic items, changes in BDI may not reflect true changes in mood but rather may translate improvement in somatic items, such as improved sleep or appetite, secondary to changes in motor signs. Therefore, we decided to split the BDI items into cognitive-affective and somatic items. The somatic items did not change significantly in the acute setting. When patients answer the BDI questions, it might be difficult FIGURE 1. UPDRS III BDI Cognitive Affective Items BDI Somatic Items Snaith-Hamilton Pleasure Scale Motor and Neuropsychiatric Performance of Parkinson s Disease Patients Receiving L-Dopa and Subthalamic Stimulation Off drug On drug Off Stimulation On Stimulation The four bars show data in the four post-operative conditions: medication off/stimulation off, medication on/stimulation off, medication off/stimulation on, and medication off/stimulation on. Significant differences with a level p.5 J Neuropsychiatry Clin Neurosci 18:3, Summer
4 analyses of visual analogous scales we evaluated three combinations of BDI scores and one SHAPS score. As a result, we favor grouping several items of one aspect of mood to get a more robust value. The second limitation refers to the point that a single L-dopa challenge might be more effective than STN-DBS in the chronic stimulation setting. We chose the L-dopa dose according to the individual amount necessary to induce an optimal motor response during pre-operative clinical testing, but the effects of a single suprathreshold L-dopa dose and chronic parameters of STN-DBS in the motor domain are comparable. Therefore, it seems plausible that the absence of an effect of STN-DBS on the hedonic tone is not simply related to the amplitude of the stimulation parameters. The third limitation points to the fact that we did not randomize the post-operative conditions of stimulation and medication. In the light of this limitation, one must discuss possible carryover effects from one condition to the other. Such a carryover effect is likely, analyzing the additive effect of STN-DBS after the significant change in hedonic tone due to L-dopa. Referring to the main result of the study (STN-DBS improves depression assessed by the BDI, but has no effect on anhedonia assessed by the SHAPS, whereas L-dopa decreases both BDI and SHAPS scores), carryover effects are not critical because the stimulation-on setting was compared with the stimulation-off setting before L-dopa was administered. Here significant STN-DBS effects were only detectable by the BDI. The fourth limitation refers to the interval of 3 minutes, which passes after changing the stimulation and medication condition. Half an hour might be too short a period to detect all changes induced by STN-DBS or medication. Two previous studies examining the emotional domain showed that the changes due to STN stimulation were evident after intervals of 3 minutes. Furthermore, P.E.I.T studies demonstrated a significant change in cerebral oxygen metabolism after a similar interval of stimulation onset in the anterior cingulate cortex, which is involved in emotional processing. 2,21 Regarding the different effects of L-dopa and STN- DBS on depressive symptoms and anhedonia, the different physiological mechanisms of both methods must be taken into consideration. L-dopa restores phasic activity of midbrain dopamine neurons necessary for the identification of primary rewards. 22 STN-DBS is supposed to suppress the pathological neuronal activity of the parkinsonian subthalamic nucleus. 23 The limbic territory of the STN is indirectly connected with the anterior cingulate cortex, which shows a hypometabolism in depressed patients suffering from Parkinson s disease. 2 Both L-dopa 25 and STN-DBS lead to a significant activation of the anterior cingulate cortex. The effect of L- dopa, in contrast, is more diffuse and involves additional mesolimbic-cortical pathways projecting from the ventral tegmental area to the limbic parts of the basal forebrain. Dopaminergic medication, therefore, is likely to have larger action, which may explain the dissociation of the effects of STN-DBS and L-dopa on mood and hedonic tone. STN-DBS seems to mimic partly the psychotropic effects of L-dopa, but does not fully replicate the motivational effects of dopaminergic stimulation. These results might also be relevant for the post-operative clinical management of Parkinson s disease patients. References 1. Lauterbach EC, Freeman A, Vogel RL: Differential DSM-III psychiatric disorder prevalence profiles in dystonia and Parkinson s disease. J Neuropsychiatry Clin Neurosci 2; 16: Lauterbach EC: The neuropsychiatry of Parkinson s disease and related disorders. Psychiatr Clin North Am 2; 27: Aarsland D, Larsen JP, Lim NG, et al: Range of neuropsychiatric disturbances in patients with Parkinson s disease. J Neurol Neurosurg Psychiatry 1999; 67: Pluck GC, Brown RG: Apathy in Parkinson s disease. J Neurol Neurosurg Psychiatry 22; 73: Isella V, Iurlaro S, Piolti R, et al: Physical anhedonia in Parkinson s disease. J Neurol Neurosurg Psychiatry 23; 7: Krack P, Batir A, Van Blercom N, et al: Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson s disease. N Engl J Med 23; 39: Herzog J, Reiff J, Krack P, et al: Manic episode with psychotic symptoms induced by subthalamic nucleus stimulation in a patient with Parkinson s disease. Mov Disord 23; 18: Houeto JL, Mesnage V, Mallet L, et al: Behavioural disorders, Parkinson s disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry 22; 72: Krack P, Kumar R, Ardouin C, et al: Mirthful laughter induced by subthalamic nucleus stimulation. Mov Disord 21; 16: Saint-Cyr JA, Trepanier LL, Kumar R, et al: Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson s disease. Brain 2; 123(Pt 1): Mattis S: Dementia Rating Scale. Odessa, Fla, Psychological Assessment Resources Inc, Schrader B, Hamel W, Weinert D, et al: Documentation of electrode localisation. Mov Disor 22; 17(suppl 3): Beck AT, Ward CH, Mendelson M, et al: An inventory for measuring depression. Arch Gen Psychiatry 1961; : J Neuropsychiatry Clin Neurosci 18:3, Summer 26
5 WITT et al. 1. Endler NS, Rutherford A, Denisoff E: Beck Depression Inventory: exploring its dimensionality in a nonclinical population. J Clin Psychol 1999; 55: Snaith RP, Hamilton M, Morley S, et al: A scale for the assessment of hedonic tone: the Snaith-Hamilton Pleasure Scale. Br J Psychiatry 1995; 167: Franz M, Lemke MR, Meyer T, et al: [German version of the Snaith-Hamilton-pleasure scale (SHAPS-D). Anhedonia in schizophrenic and depressive patients] Fortschr Neurol Psychiatr 1998; 66: Funkiewiez A, Ardouin C, Krack P, et al: Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson s disease. Mov Disord 23; 18: Maricle RA, Nutt JG, Valentine RJ, et al: Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson s disease: a double-blind, placebo-controlled study. Neurology 1995; 5: Schneider F, Habel U, Volkmann J, et al: Deep brain stimulation of the subthalamic nucleus enhances emotional processing in Parkinson disease. Arch Gen Psychiatry 23; 6: Hilker R, Voges J, Weisenbach S, et al: Subthalamic nucleus stimulation restores glucose metabolism in associative and limbic cortices and in cerebellum: evidence from a FDG-PET study in advanced Parkinson s disease. J Cereb Blood Flow Metab 2; 2: Limousin P, Greene J, Pollak P, et al: Changes in cerebral activity pattern due to subthalamic nucleus or internal pallidum stimulation in Parkinson s disease. Ann Neurol 1997; 2: Schultz W: Multiple reward signals in the brain. Nat Rev Neurosci 2; 1: Garcia L, Audin J, D Alessandro G, et al: Dual effect of highfrequency stimulation on subthalamic neuron activity. J Neurosci 23; 23: Ring HA, Bench CJ, Trimble MR, et al: Depression in Parkinson s disease: a positron emission study. Br J Psychiatry 199; 165: Buhmann C, Glauche V, Sturenburg HJ, et al: Pharmacologically modulated fmri cortical responsiveness to levodopa in drug-naive hemiparkinsonian patients. Brain 23; 126(Pt 2): J Neuropsychiatry Clin Neurosci 18:3, Summer
A Funkiewiez, C Ardouin, E Caputo, P Krack, V Fraix, H Klinger, S Chabardes, K Foote, A-L Benabid, P Pollak...
834 PAPER Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson s disease A Funkiewiez, C Ardouin, E Caputo, P Krack, V Fraix, H Klinger,
More informationDeep Brain Stimulation: Patient selection
Deep Brain Stimulation: Patient selection Halim Fadil, MD Movement Disorders Neurologist Kane Hall Barry Neurology Bedford/Keller, TX 1991: Thalamic (Vim) DBS for tremor Benabid AL, et al. Lancet. 1991;337(8738):403-406.
More informationORIGINAL CONTRIBUTION. Improvement in Parkinson Disease by Subthalamic Nucleus Stimulation Based on Electrode Placement
ORIGINAL CONTRIBUTION Improvement in Parkinson Disease by Subthalamic Nucleus Stimulation Based on Electrode Placement Effects of Reimplantation Mathieu Anheim, MD; Alina Batir, MD; Valérie Fraix, MD;
More informationA lthough levodopa treatment remains the gold standard
1640 PAPER Stimulation of the subthalamic nucleus in Parkinson s disease: a 5 year follow up W M M Schüpbach, N Chastan, M L Welter, J L Houeto, V Mesnage, A M Bonnet, V Czernecki, D Maltête, A Hartmann,
More informationORIGINAL CONTRIBUTION. Subthalamic Stimulation in Parkinson Disease
Subthalamic Stimulation in Parkinson Disease A Multidisciplinary Approach ORIGINAL CONTRIBUTION J. L. Houeto, MD; P. Damier, MD, PhD; P. B. Bejjani, MD; C. Staedler, MD; A. M. Bonnet, MD; I. Arnulf, MD;
More informationDeep brain stimulation (DBS) is now well established
Pallidal Stimulation in Parkinson s Disease Does Not Induce Apathy Clément Lozachmeur, M.D. Sophie Drapier, M.D. Gabriel Robert, M.D., Ph.D. Thibaut Dondaine Bruno Laviolle, M.D., Ph.D. Paul Sauleau, M.D.
More informationThe Effect of Pramipexole on Depressive Symptoms in Parkinson's Disease.
Kobe J. Med. Sci., Vol. 56, No. 5, pp. E214-E219, 2010 The Effect of Pramipexole on Depressive Symptoms in Parkinson's Disease. NAOKO YASUI 1, KENJI SEKIGUCHI 1, HIROTOSHI HAMAGUCHI 1, and FUMIO KANDA
More informationEvidence compendium. Research study summaries supporting the use of Medtronic deep brain stimulation (DBS) for Parkinson s disease
Evidence compendium Research study summaries supporting the use of Medtronic deep brain stimulation (DBS) for Parkinson s disease CONTENTS Introduction... 4 Index of study summaries... 6 Parkinson s disease
More informationDeep Brain Stimulation: Indications and Ethical Applications
Deep Brain Stimulation Overview Kara D. Beasley, DO, MBe, FACOS Boulder Neurosurgical and Spine Associates (303) 562-1372 Deep Brain Stimulation: Indications and Ethical Applications Instrument of Change
More informationDeep Brain Stimulation for Parkinson s Disease & Essential Tremor
Deep Brain Stimulation for Parkinson s Disease & Essential Tremor Albert Fenoy, MD Assistant Professor University of Texas at Houston, Health Science Center Current US Approvals Essential Tremor and Parkinsonian
More informationLong-term outcome of subthalamic nucleus deep brain stimulation for Parkinson s disease using an MRI-guided and MRI-verified approach
RESEARCH PAPER Long-term outcome of subthalamic nucleus deep brain stimulation for Parkinson s disease using an MRI-guided and MRI-verified approach Iciar Aviles-Olmos, Zinovia Kefalopoulou, Elina Tripoliti,
More informationCONTINUOUS APOMORPHINE INFUSION (CAI) AND NEUROPSYCHIATRIC DISORDERS IN PATIENTS WITH ADVANCED PARKINSON S DISEASE: A FOLLOW-UP OF TWO YEARS.
Arch. Gerontol. Geriatr. Suppl. 9 (2004) 291 296 0167-4943/$ see front matter # 2004 Elsevier Ireland Ltd. All rights reserved CONTINUOUS APOMORPHINE INFUSION (CAI) AND NEUROPSYCHIATRIC DISORDERS IN PATIENTS
More informationCognitive and Behavioural Changes After Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson s Disease
17 Cognitive and Behavioural Changes After Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson s Disease Antonio Daniele, Pietro Spinelli and Chiara Piccininni Istituto di Neurologia, Università
More informationB ilateral continuous high frequency stimulation of the
PAPER Behavioural disorders, Parkinson s disease and subthalamic stimulation J L Houeto, V Mesnage, L Mallet, B Pillon, M Gargiulo, S Tezenas du Moncel, A M Bonnet, B Pidoux, D Dormont, P Cornu, Y Agid...
More informationBasal ganglia motor circuit
Parkinson s Disease Basal ganglia motor circuit 1 Direct pathway (gas pedal) 2 Indirect pathway (brake) To release or augment the tonic inhibition of GPi on thalamus Direct pathway There is a tonic inhibition
More informationArticle. Reference. Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. ARDOUIN, Claire, et al.
Article Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation ARDOUIN, Claire, et al. Reference ARDOUIN, Claire, et al. Pathological gambling in Parkinson's disease
More informationNeuropsychiatric Effects of Subthalamic Nucleus Deep Brain Stimulation in Parkinson Disease in China: A Prospectively Controlled Study
Research Neuropsychiatric Effects of Subthalamic Nucleus Deep Brain Stimulation in Parkinson Disease in China: A Yi Xie, Junjian Zhang, Jinsong Xiao Abstract Background: The effects of subthalamic nucleus
More informationDeep brain stimulation (DBS) has been
TOPIC RESEARCH HUMAN CLINICAL STUDIES RESEARCH HUMAN CLINICAL STUDIES Do Stable Patients With a Premorbid Depression History Have a Worse Outcome After Deep Brain Stimulation for Parkinson Disease? Michael
More informationLinköping University Post Print. Patient-specific models and simulations of deep brain stimulation for postoperative follow-up
inköping University Post Print Patient-specific models and simulations of deep brain stimulation for postoperative follow-up Mattias Åström, Elina Tripoliti, Irene Martinez-Torres, udvic U. Zrinzo, Patricia
More informationThe possibility of deep brain stimulation to treat eating disorders.
The possibility of deep brain stimulation to treat eating disorders. Andres M Lozano MD PhD Professor and Dan Family Chair of Neurosurgery Canada Research Chair in Neuroscience Toronto Western Hospital
More informationValidity and Reliability Assessment of a Japanese Version of the Snaith-Hamilton Pleasure Scale
ORIGINAL ARTICLE Validity and Reliability Assessment of a Japanese Version of the Snaith-Hamilton Pleasure Scale Hiroshi Nagayama 1, Shin-ichiro Kubo 2, Taku Hatano 2, Shinsuke Hamada 3, Tetsuya Maeda
More informationMaking Things Happen 2: Motor Disorders
Making Things Happen 2: Motor Disorders How Your Brain Works Prof. Jan Schnupp wschnupp@cityu.edu.hk HowYourBrainWorks.net On the Menu in This Lecture In the previous lecture we saw how motor cortex and
More informationPostoperative apathy can neutralise benefits in quality of life after subthalamic stimulation for Parkinson s disease
Article The hidden sister of motor fluctuations in Parkinson's disease: A review on nonmotor fluctuations MARTINEZ-FERNANDEZ, Raul, et al. Reference MARTINEZ-FERNANDEZ, Raul, et al. The hidden sister of
More informationdoi: /brain/aws078 Brain 2012: 135;
doi:10.1093/brain/aws078 Brain 2012: 135; 1463 1477 1463 BRAIN A JOURNAL OF NEUROLOGY Subthalamic stimulation in Parkinson s disease: restoring the balance of motivated behaviours Eugénie Lhommée, 1,2
More informationSurgical Treatment of Movement Disorders. Surgical Treatment of Movement Disorders. New Techniques: Procedure is safer and better
Surgical Treatment of Movement Stephen Grill, MD, PHD Johns Hopkins University and Parkinson s and Movement Center of Maryland Surgical Treatment of Movement Historical Aspects Preoperative Issues Surgical
More informationDBS-implanted Parkinson's Disease Patients Show Better Olfaction Than Those Treated Medically
http://escholarship.umassmed.edu/neurol_bull DBS-implanted Parkinson's Disease Patients Show Better Olfaction Than Those Treated Medically Mary Linton Peters, Paula Ravin, Peter Novak, Anthony M. Burrows,
More informationPatient selection for surgery: Parkinson s disease
Patient selection for surgery: Parkinson s disease Dr. María C. Rodríguez-Oroz Neurology and Neuroscience. University Hospital Donostia, Research Institute BioDonostia, Ikerbasque Senior Researcher San
More informationdoi: /brain/awt067 Brain 2013: 136; Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil
doi:10.1093/brain/awt067 Brain 2013: 136; 1568 1577 1568 BRAIN A JOURNAL OF NEUROLOGY Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil Stéphane Thobois, 1,2 Eugénie
More informationBrain Advance Access published March 17, doi: /brain/awq032 Brain 2010: Page 1 of 17 1
Brain Advance Access published March 17, 2010 doi:10.1093/brain/awq032 Brain 2010: Page 1 of 17 1 BRAIN A JOURNAL OF NEUROLOGY Non-motor dopamine withdrawal syndrome after surgery for Parkinson s disease:
More informationHallucinations and conscious access to visual inputs in Parkinson s disease
Supplemental informations Hallucinations and conscious access to visual inputs in Parkinson s disease Stéphanie Lefebvre, PhD^1,2, Guillaume Baille, MD^4, Renaud Jardri MD, PhD 1,2 Lucie Plomhause, PhD
More informationSee Policy CPT/HCPCS CODE section below for any prior authorization requirements
Effective Date: 1/1/2019 Section: SUR Policy No: 395 1/1/19 Medical Policy Committee Approved Date: 8/17; 2/18; 12/18 Medical Officer Date APPLIES TO: Medicare Only See Policy CPT/HCPCS CODE section below
More informationOverweight after deep brain stimulation of the subthalamic nucleus in Parkinson disease: long term follow-up
1 CHU Clermont-Ferrand, Department of Neurology, Gabriel Montpied Hospital, Clermont-Ferrand, France; 2 Univ Clermont 1, UFR Medecine, Clermont-Ferrand, France; 3 INRA, Centre Clermont-Ferrand Theix, Unite
More informationSurgery for Parkinson s disease improves disability but not impairment components of the UPDRS-II
Parkinsonism and Related Disorders 13 (2007) 399 405 www.elsevier.com/locate/parkreldis Surgery for Parkinson s disease improves disability but not impairment components of the UPDRS-II A. Haffenden, U.
More informationDEEP BRAIN STIMULATION (DBS) is a standard treatment
1320 ORIGINAL ARTICLE Fast-Track Programming and Rehabilitation Model: A Novel Approach to Postoperative Deep Brain Stimulation Patient Care David B. Cohen, MD, Michael Y. Oh, MD, Susan M. Baser, MD, Cindy
More informationAlthough the motor benefits of deep brain stimulation
REGULAR ARTICLES Deep brain stimulation of the subthalamic nucleus (STN DBS) in Parkinson s disease (PD) improves motor functioning but has variable effects on mood. Little is known about the relationship
More informationCell transplantation in Parkinson s disease
Cell transplantation in Parkinson s disease Findings by SBU Alert Published September 18, 2001 Revised November 7, 2003 Version 2 Technology and target group: In Parkinsons disease, the brain cells that
More informationRange of neuropsychiatric disturbances in patients with Parkinson s disease
492 Section of Geriatric Psychiatry, Rogaland Psychiatric Hospital D Aarsland N G Lim C Janvin Department of Neurology, Central Hospital of Rogaland, Stavanger, Norway J P Larsen K Karlsen E Tandberg Departments
More informationmodulation of multiple brain networks.
Neuroanatomy of Deep Brain Stimulation: modulation of multiple brain networks. Dr. med. Ettore A. Accolla Maladie de Parkinson: un diagnostic clinique 1. Bradykinésie 2. Tremblement de repos (4-6 Hz) 3.
More informationDeep Brain Stimulation
Deep Brain Stimulation Patient and caregiver education Valérie Fraix, MD, PhD and Emmanuelle Schmitt Neurology Department, Grenoble-Alpes University Hospital Grenoble-Alpes University, INSERM U1216 F-38000
More informationHealth related quality of life in Parkinson s disease: a prospective longitudinal study
584 Department of Neurology, Central Hospital of Rogaland, Postbox 8100, N-4003 Stavanger, Norway K H Karlsen E Tandberg J P Larsen Department of Psychiatry D Årsland Correspondence to: Professor Jan P
More informationFive-Year Follow-up of Bilateral Stimulation of the Subthalamic Nucleus in Advanced Parkinson s Disease
The new england journal of medicine original article Five-Year Follow-up of Bilateral Stimulation of the Subthalamic Nucleus in Advanced Parkinson s Disease Paul Krack, M.D., Ph.D., Alina Batir, M.D.,
More informationyears; baseline off-state Unified Parkinson s Disease Rating Scale (UPDRS) motor ratings 24.6 ± 6.8).
Jourdain et al. 1 Supplemental Data Supplemental Methods Subjects We studied 28 PD subjects (20 men and 8 women; age 61.0 ± 9.6 (mean ± SD) years; duration 8.7 ± 9.6 years; baseline off-state Unified Parkinson
More informationParkinson disease: Parkinson Disease
Surgical Surgical treatment treatment for for Parkinson disease: Parkinson Disease the Present and the Future the Present and the Future Olga Klepitskaya, MD Associate Professor of Neurology Co-Director,
More informationQuality of Life in Patients with Parkinson s Disease
Quality of Life in Patients with Parkinson s Disease Seuk Kyung Hong, M.D., Kyung Won Park, M.D., Jae Kwan Cha, M.D., Sang Ho Kim, M.D., Dong Yeol Chun, M.D.*, Chang Kook Yang, M.D.*, Jae Woo Kim, M.D.
More informationDeep Brain Stimulation. Is It Right for You?
Deep Brain Stimulation Is It Right for You? Northwestern Medicine Deep Brain Stimulation What is DBS? Northwestern Medicine Central DuPage Hospital is a regional destination for the treatment of movement
More informationStudy protocol. Resistance versus Balance Training to improve postural control in Parkinson s disease
Study protocol (English translation of the german study protocol; for the complete study protocol see german version) Resistance versus Balance Training to improve postural control in Parkinson s disease
More informationD eep brain stimulation of the subthalamic nucleus (STN
PAPER Disease progression continues in patients with advanced Parkinson s disease and effective subthalamic nucleus stimulation R Hilker*, A T Portman*, J Voges, M J Staal, L Burghaus, T van Laar, A Koulousakis,
More informationEDITORS PICK CLINICAL SIGNIFICANCE OF APATHY IN PARKINSON S DISEASE. Kinan Muhammed, *Masud Husain
EDITORS PICK The significant health burden that apathy creates for patients with Parkinson s disease is revealed in the following article by Muhammed and Husain; also highlighted are the difficulties of
More informationWHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019
WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019 YOUNG ONSET PARKINSON S DISEASE Definition: Parkinson s disease diagnosed
More informationneuropsychiatric effects of subthalamic neurostimulation in Parkinson disease
reviews neuropsychiatric effects of subthalamic neurostimulation in Parkinson disease Jens Volkmann, Christine Daniels and Karsten Witt Abstract Neurostimulation of the subthalamic nucleus (STN) is an
More informationFactors Related to Outcomes of Subthalamic Deep Brain Stimulation in Parkinson s Disease
online ML Comm www.jkns.or.kr http://dx.doi.org/0.3340/jkns.203.54.2.8 J Korean Neurosurg Soc 54 : 8-24, 203 Print ISSN 2005-3 On-line ISSN 598-8 Copyright 203 The Korean Neurosurgical Society Clinical
More informationC. Moreau, MD L. Defebvre, MD, PhD A. Destée, MD, PhD S. Bleuse, PhD F. Clement, MD J.L. Blatt, MD, PhD P. Krystkowiak, MD, PhD D.
ARTICLES STN-DBS frequency effects on freezing of gait in advanced Parkinson disease C. Moreau, MD L. Defebvre, MD, PhD A. Destée, MD, PhD S. Bleuse, PhD F. Clement, MD J.L. Blatt, MD, PhD P. Krystkowiak,
More informationBrain Mechanisms of Emotion 1 of 6
Brain Mechanisms of Emotion 1 of 6 I. WHAT IS AN EMOTION? A. Three components (Oately & Jenkins, 1996) 1. caused by conscious or unconscious evaluation of an event as relevant to a goal that is important
More informationGangli della Base: un network multifunzionale
Gangli della Base: un network multifunzionale Prof. Giovanni Abbruzzese Centro per la Malattia di Parkinson e i Disordini del Movimento DiNOGMI, Università di Genova IRCCS AOU San Martino IST Basal Ganglia
More informationAcute and Chronic Mood and Apathy Outcomes from a Randomized Study of Unilateral STN and GPi DBS
OPEN ACCESS Citation: Okun MS, Wu SS, Fayad S, Ward H, Bowers D, et al. (214) Acute and Chronic Mood and Apathy Outcomes from a Randomized Study of Unilateral STN and GPi DBS. PLoS ONE 9(12): e11414. doi:1.171/journal.pone.11414
More informationNIH, American Parkinson Disease Association (APDA), Greater St. Louis Chapter of the APDA, McDonnell Center for Higher Brain Function, Barnes-Jewish
Mechanism of Action of Deep Brain Stimulation In Parkinson Disease Samer D. Tabbal, M.D. Associate Professor of Neurology Washington University at St Louis Department of Neurology June 2011 Conflict of
More informationnucleus accumbens septi hier-259 Nucleus+Accumbens birnlex_727
Nucleus accumbens From Wikipedia, the free encyclopedia Brain: Nucleus accumbens Nucleus accumbens visible in red. Latin NeuroNames MeSH NeuroLex ID nucleus accumbens septi hier-259 Nucleus+Accumbens birnlex_727
More informationPunit Agrawal, DO Clinical Assistant Professor of Neurology Division of Movement Disorders OSU Department of Neurology
Deep Brain Stimulation for Movement Disorders Punit Agrawal, DO Clinical Assistant Professor of Neurology Division of Movement Disorders OSU Department of Neurology History of DBS 1 History of DBS 1987
More informationDBS efficacia, complicanze in cronico e nuovi orizzonti terapeutici
DBS efficacia, complicanze in cronico e nuovi orizzonti terapeutici TECNICHE DI NEUROMODULAZIONE Invasiva: odeep Brain Stimulation Non Invasiva: o Transcranial Magnetic Stimulation (TMS) o Transcranial
More informationPsychostimulant Effect of Dopaminergic Treatment and Addictions in Parkinson s Disease
RESEARCH ARTICLE Psychostimulant Effect of Dopaminergic Treatment and Addictions in Parkinson s Disease Benoit Delpont, MD, 1 Eugenie Lhommee, MA, 1,2 Helène Klinger, MA, 3,4 Emmanuelle Schmitt, MA, 1,2
More informationNature, prevalence and clinical significance. Barcelona, Spain
Nature, prevalence and clinical significance Jaime Kulisevsky Barcelona, Spain 1 Non motor (neuropsychiatric) symptoms are an integral part of Parkinson s s disease (PD) Affective disorders And are associated
More informationAnosognosia, or loss of insight into one s cognitive
REGULAR ARTICLES Anosognosia Is a Significant Predictor of Apathy in Alzheimer s Disease Sergio E. Starkstein, M.D., Ph.D. Simone Brockman, M.A. David Bruce, M.D. Gustavo Petracca, M.D. Anosognosia and
More informationdoi: /brain/awq221 Brain 2010: 133;
doi:10.1093/brain/awq221 Brain 2010: 133; 2664 2676 2664 BRAIN A JOURNAL OF NEUROLOGY Motor and cognitive outcome in patients with Parkinson s disease 8 years after subthalamic implants Alfonso Fasano,
More informationPACEMAKERS ARE NOT JUST FOR THE HEART! Ab Siadati MD
PACEMAKERS ARE NOT JUST FOR THE HEART! Ab Siadati MD WHAT IS DEEP BRAIN STIMULATION? WHY SHOULD YOU CONSIDER DBS SURGERY FOR YOUR PATIENTS? HOW DOES DBS WORK? DBS electrical stimulation overrides abnormal
More informationEMERGING TREATMENTS FOR PARKINSON S DISEASE
EMERGING TREATMENTS FOR PARKINSON S DISEASE Katerina Markopoulou, MD, PhD Director Neurodegenerative Diseases Program Department of Neurology NorthShore University HealthSystem Clinical Assistant Professor
More informationLong-term follow up of subthalamic nucleus stimulation in Parkinson s disease
oped parallel to a progressive cerebral disease. These findings are supported by other recent reports showing that EDS correlates with more advanced PD. 9 The close correlation between persistent and new
More informationModulation of the Neural Circuitry Underlying Obsessive-Compulsive Disorder
BRAIN STIMULATION LABORATORY Modulation of the Neural Circuitry Underlying Obsessive-Compulsive Disorder OCD Awareness Day NOLAN WILLIAMS, M.D. Instructor Department of Psychiatry Stanford University October
More informationParkinson s disease (PD) affects as many as 1 million
Underlying Neurobiology and Clinical Correlates of Mania Status After Subthalamic Nucleus Deep Brain Stimulation in Parkinson s Disease: A Review of the Literature Amit Chopra, M.B.B.S. Susannah J. Tye,
More informationVL VA BASAL GANGLIA. FUNCTIONAl COMPONENTS. Function Component Deficits Start/initiation Basal Ganglia Spontan movements
BASAL GANGLIA Chris Cohan, Ph.D. Dept. of Pathology/Anat Sci University at Buffalo I) Overview How do Basal Ganglia affect movement Basal ganglia enhance cortical motor activity and facilitate movement.
More informationT he prevalence of Parkinson s disease (PD) is nearly 1% in
708 PAPER Donepezil for cognitive impairment in Parkinson s disease: a randomised controlled study D Aarsland, K Laake, J P Larsen, C Janvin... See end of article for authors affiliations... Correspondence
More informationSurgical Management of Parkinson s Disease
Surgical Management of Parkinson s Disease Shyamal H. Mehta MD, PhD Assistant Professor of Neurology, Movement Disorders Division Mayo Clinic College of Medicine Mayo Clinic, Arizona 2016 MFMER slide-1
More informationAre Behavioural Disorders a separate nosological category of disorders?
249 Review Article Are Behavioural Disorders a separate nosological category of disorders? Shrirang Bakhle 1 1 Consulting Physician, Mumbai. E-mail ss.bakhle@gmail.com ABSTRACT The term Behavioural Disorders
More informationB ilateral chronic subthalamic nucleus stimulation
PAPER Functional improvement after subthalamic stimulation in Parkinson s disease: a non-equivalent controlled study with 12 24 month follow up M Capecci, R A Ricciuti, D Burini, V G Bombace, L Provinciali,
More informationLong-Term Results of a Multicenter Study on Subthalamic and Pallidal Stimulation in Parkinson s Disease
Movement Disorders Vol. 25, No. 5, 2010, pp. 578 586 Ó 2010 Movement Disorder Society Long-Term Results of a Multicenter Study on Subthalamic and Pallidal Stimulation in Parkinson s Disease Elena Moro,
More informationThe validity of the hospital anxiety and depression scale and the geriatric depression scale in Parkinson s disease
Behavioural Neurology 17 (2006) 109 115 109 IOS Press The validity of the hospital anxiety and depression scale and the geriatric depression scale in Parkinson s disease Federica Mondolo a,, Marjan Jahanshahi
More informationA Longitudinal Evaluation of Health-Related Quality of Life of Patients with Parkinson s Disease
Volume 12 Number 2 2009 VALUE IN HEALTH A Longitudinal Evaluation of Health-Related Quality of Life of Patients with Parkinson s Disease Martine Visser, PhD, 1 Dagmar Verbaan, MSc, 1 Stephanie van Rooden,
More informationSafinamide: un farmaco innovativo con un duplice meccanismo d azione
Safinamide: un farmaco innovativo con un duplice meccanismo d azione AINAT Sardegna Cagliari, 26 novembre 2016 Carlo Cattaneo Corporate Medical Advisor CNS & Rare Diseases Reichmann H. et al., European
More information10/13/2017. Disclosures. Deep Brain Stimulation in the Treatment of Movement Disorders. Deep Brain Stimulation: Objectives.
Deep Brain Stimulation in the Treatment of Movement Disorders Disclosures None Eleanor K Orehek, M.D. Movement Disorders Specialist Noran Neurological Clinic 1 2 Objectives To provide an overview of deep
More informationArticle. Reference. Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment. PAGONABARRAGA, Javier, et al.
Article Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment PAGONABARRAGA, Javier, et al. Reference PAGONABARRAGA, Javier, et al. Apathy in Parkinson's disease:
More informationKeywords: deep brain stimulation; subthalamic nucleus, subjective visual vertical, adverse reaction
Re: Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation Norbert Kovacs 1*, Jozsef Janszky 1, Ferenc
More informationNEURAL CONTROL OF MOVEMENT: ENGINEERING THE RHYTHMS OF THE BRAIN
NEURAL CONTROL OF MOVEMENT: ENGINEERING THE RHYTHMS OF THE BRAIN Madeleine Lowery School of Electrical and Electronic Engineering Centre for Biomedical Engineering University College Dublin Parkinson s
More informationContinuous dopaminergic stimulation
Continuous dopaminergic stimulation Angelo Antonini Milan, Italy GPSRC CNS 172 173 0709 RTG 1 As PD progresses patient mobility becomes increasingly dependent on bioavailability of peripheral levodopa
More informationThe Effects of Bilateral Subthalamic Nucleus Stimulation on Cognitive and Neuropsychiatric Functions in Parkinson s Disease: A Case-Control Study #
The Effects of Bilateral Subthalamic Nucleus Stimulation on Cognitive and Neuropsychiatric Functions in Parkinson s Disease: A Case-Control Study # Reza Mahdavi 1, SeyedKazem Malakouti 2 *, GholamAli Shahidi
More informationSurgical Treatment for Movement Disorders
Surgical Treatment for Movement Disorders Seth F Oliveria, MD PhD The Oregon Clinic Neurosurgery Director of Functional Neurosurgery: Providence Brain and Spine Institute Portland, OR Providence St Vincent
More informationRapid assessment of gait and speech after subthalamic deep brain stimulation
SNI: Stereotactic, a supplement to Surgical Neurology International OPEN ACCESS For entire Editorial Board visit : http://www.surgicalneurologyint.com Editor Antonio A. F. DeSalles, MD University of California,
More informationCognition following bilateral deep brain stimulation surgery of the subthalamic nucleus for Parkinson s disease
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY Int J Geriatr Psychiatry 2009; 24: 443 451. Published online 17 November 2008 in Wiley InterScience (www.interscience.wiley.com).2149 REVIEW ARTICLE Cognition
More informationNeurosurgery 61[ONS Suppl 2]:ONS346 ONS357, 2007
Yasin Temel, M.D., Ph.D. Department of Neurosurgery, University Hospital Maastricht, and European Graduate School of Neuroscience, Poldi Wilbrink, M.D. Department of Neurosurgery, University Hospital Maastricht,
More informationThis article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and
This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution
More informationLong-Term Cognitive Profile and Incidence of Dementia After STN-DBS in Parkinson s Disease
Movement Disorders Vol. 22, No. 7, 2007, pp. 974-981 2007 Movement Disorder Society Long-Term Cognitive Profile and Incidence of Dementia After STN-DBS in Parkinson s Disease Selma Aybek, MD, 1 Aline Gronchi-Perrin,
More informationMaking Every Little Bit Count: Parkinson s Disease. SHP Neurobiology of Development and Disease
Making Every Little Bit Count: Parkinson s Disease SHP Neurobiology of Development and Disease Parkinson s Disease Initially described symptomatically by Dr. James Parkinson in 1817 in An Essay on the
More informationIndications. DBS for Tremor. What is the PSA? 6/08/2014. Tremor. 1. Tremor. 2. Gait freezing/postural instability. 3. Motor fluctuations
Indications Deep brain stimulation for Parkinson s disease A Tailored Approach 1. Tremor 2. Gait freezing/postural instability Wesley Thevathasan FRACP DPhil.Oxf 3. Motor fluctuations Consultant Neurologist,
More informationCoordinated Reset Neuromodulation for Parkinson s Disease: Proof-of-Concept Study
BRIEF REPORT Coordinated Reset Neuromodulation for Parkinson s Disease: Proof-of-Concept Study Ilya Adamchic, MD, 1 Christian Hauptmann, PhD, 1 Utako Brigit Barnikol, MD, 1,2,3,4 Norbert Pawelczyk, 1 Oleksandr
More informationbiological psychology, p. 40 The study of the nervous system, especially the brain. neuroscience, p. 40
biological psychology, p. 40 The specialized branch of psychology that studies the relationship between behavior and bodily processes and system; also called biopsychology or psychobiology. neuroscience,
More informationNon-therapeutic and investigational uses of non-invasive brain stimulation
Non-therapeutic and investigational uses of non-invasive brain stimulation Robert Chen, MA, MBBChir, MSc, FRCPC Catherine Manson Chair in Movement Disorders Professor of Medicine (Neurology), University
More informationMeasuring symptom change in patients with Parkinson s disease
Age and Ageing 2000; 29: 41 45 2000, British Geriatrics Society Measuring symptom change in patients with Parkinson s disease JOHN E. HARRISON, SARAH PRESTON 1,STAVIA B. BLUNT 1 CeNeS Ltd, Compass House,
More informationDeep Brain Stimulation
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationO R I G I N A L A R T I C L E
Neuroendocrinology Letters Volume 28 No. 1 2007 Increase in body weight is a non-motor side effect of deep brain stimulation of the subthalamic nucleus in Parkinson s disease Lucie Novakova, Evzen Ruzicka,
More informationService Line: Rapid Response Service Version: 1.0 Publication Date: December 14, 2018 Report Length: 45 Pages
CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Deep Brain Stimulation for Parkinson s Disease: A Review of Clinical Effectiveness, Cost- Effectiveness, and Guidelines Service Line: Rapid
More informationWhat goes wrong with balance in Parkinson s Disease? Fay B Horak, PhD, PT Professor of Neurology Oregon Health and Science. CoM
What goes wrong with balance in Parkinson s Disease? Fay B Horak, PhD, PT Professor of Neurology Oregon Health and Science CoM CoM Course Objectives Understand different types of balance systems affected
More information